EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies

André Lieber, Hans-Peter Kiem

Molecular Therapy · 2023

DOI: 10.1016/j.ymthe.2023.09.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von André Lieber und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Gene Editing, Hematopoietic Stem Cells, Hemoglobinopathies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There has been tremendous progress in the field of hematopoietic stem cell (HSC) gene therapy, especially for hemoglobinopathies. Recently, bluebird bio received FDA approval to use their lentiviral vector (delivering a functional beta globin gene) for the treatment of transfusion-dependent thalassemia, and approval to use this vector for the treatment of sickle cell disease (SCD) is expected in the near future. Similar promising results have been observed with CRISPR-mediated editing, and Vertex/CRISPR are also nearing approval for their approach to reactivate fetal hemoglobin. However, what these approaches have in common is that they are all carried out ex vivo (“outside the body”) and require sophisticated infrastructure that would not generally be available in low- or middle-income countries or, for that matter, in resource-limited regions in high-income countries. In addition, these ex vivo approaches are very costly, with approved treatments expected to cost $2 to $3 million dollars, and they will not be a viable option for the millions of people affected in less-affluent countries. Thus, while promising and important, current ex vivo gene therapies are not a realistic option for most patients and would likely provide curative therapy for fewer than 1% of patients with SCD worldwide. If, however, one could deliver the gene therapy or editing tools and target HSC directly in vivo, the process would possibly be far less complicated, less expensive, and more accessible to those in need, wherever they may reside (Figure 1).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingHematopoietic Stem CellsHemoglobinopathiesAnimalsHumansCRISPR-Cas SystemsGenetic TherapyHematopoietic Stem Cell Transplantation

Autor:innen und Institutionen

  • University of Washington, Seattle, WA, USA.
  • University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: hkiem@fredhutch.org.

Zitieren

APA

Lieber, A., & Kiem, H. P. (2023). Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.09.006

Vancouver

Lieber A, Kiem HP. Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.09.006

BibTeX
@article{Lieber2023,
  author = {Lieber, André and Kiem, Hans-Peter},
  title = {Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies},
  journal = {Molecular Therapy},
  year = {2023},
  doi = {10.1016/j.ymthe.2023.09.006}
}
Kostenlos starten →